Evolus Inc
$ 4.63
4.28%
15 Apr - close price
- Market Cap 288,866,000 USD
- Current Price $ 4.63
- High / Low $ 4.64 / 4.38
- Stock P/E N/A
- Book Value -0.36
- EPS -0.80
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.10 %
- ROE -187.30 %
- 52 Week High 12.28
- 52 Week Low 3.86
About
Evolus, Inc., a high-performance beauty company, provides aesthetic medical products for physicians and their patients in the United States. The company is headquartered in Newport Beach, California.
Analyst Target Price
$14.67
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-03 | 2025-11-05 | 2025-08-05 | 2025-05-05 | 2025-03-04 | 2024-11-06 | 2024-07-31 | 2024-05-07 | 2024-03-07 | 2023-11-07 | 2023-08-02 | 2023-05-09 |
| Reported EPS | 0.0132 | -0.24 | -0.27 | -0.17 | 0.0139 | -0.16 | -0.04 | -0.09 | -0.12 | -0.16 | -0.19 | -0.15 |
| Estimated EPS | 0.0373 | -0.15 | -0.1 | -0.1 | 0.0223 | -0.1 | -0.05 | -0.1 | -0.07 | -0.17 | -0.19 | -0.15 |
| Surprise | -0.0241 | -0.09 | -0.17 | -0.07 | -0.0084 | -0.06 | 0.01 | 0.01 | -0.05 | 0.01 | 0 | 0 |
| Surprise Percentage | -64.6113% | -60% | -170% | -70% | -37.6682% | -60% | 20% | 10% | -71.4286% | 5.8824% | 0% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.22 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EOLS
2026-04-14 07:39:24
This entry indicates the availability of the Q4 2025 earnings call transcript for Evolus, Inc. (NASDAQ:EOLS). This crucial document provides a detailed overview of the company's financial performance and strategic outlook discussed during the call. Investors and analysts can use this resource to gain insights into the company's recent results and future plans.
2026-04-11 01:38:48
This article from GuruFocus examines Evolus (LTS:0K16) Price-to-Book (PB) Ratio as of April 11, 2026. It elaborates on the calculation of the PB Ratio, provides historical data and industry comparisons, and notes that Evolus' stock appears to be undervalued according to GuruFocus' GF Value™. The company's business description highlights its focus on aesthetic medicine with its flagship product, Jeuveau.
2026-03-31 16:11:35
Evolus, Inc. announced that its management team will participate in a fireside chat and investor meetings at the Needham 25th Annual Virtual Healthcare Conference on Tuesday, April 14, 2026, at 3:45 PM ET. The fireside chat will be accessible via their Investor Relations page, with a replay available for 90 days. Evolus is a performance beauty company focused on aesthetic injectables like Jeuveau and Evolysse.
2026-03-31 11:39:42
Evolus, Inc. announced its management team will participate in a fireside chat and investor meetings at the Needham 25th Annual Virtual Healthcare Conference on April 14, 2026, at 3:45 PM ET. The performance beauty company focuses on building an aesthetic portfolio of consumer brands and redefining the aesthetic injectable market. A webcast of the fireside chat will be available on the Investor Relations page of the Evolus website.
2026-03-27 16:39:55
Evolus, Inc. (NASDAQ:EOLS) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $16.00. Despite this, insiders have recently sold a significant number of shares, and the company's stock is trading near its 1-year low after missing quarterly EPS estimates. Institutional investors, however, have shown mixed activity, with some increasing and some decreasing their stakes.
2026-03-26 15:10:05
The Vanguard Group has filed an amended Schedule 13G for Evolus (EOLS), reporting 0% beneficial ownership of the common stock. This change is due to an internal realignment within Vanguard, leading to disaggregated reporting by its subsidiaries in accordance with SEC Release No. 34-39538, effective January 12, 2026. The filing explicitly states that this is a procedural change in reporting structure and does not indicate a sale of shares by Vanguard.
